Biosensors & Bioelectronics · Jan 12, 2026
Single-vesicle profiling of multiple biomarkers on serum EVs via EV-CATCH and nano-flow cytometry for clinical stratification of Alzheimer's disease
By Zhang Y, Zhao L, Yu X et al.
Alzheimer's disease (AD) is a kind of progressive neurodegenerative disorder caused by neuron damage, which imposed significant economic and social burdens. Early and precise AD diagnosis remains an obstacle in the clinic, primarily attributable to the absence of simple, noninvasive, and reliable detection methods. Extracellular vesicles (EVs) carry molecular cargos reflecting cellular origin and can cross the blood-brain barrier, serving as promising biomarkers for neurological diseases. Herein, we propose a novel EV-CATCH-based nano-flow cytometry strategy for rapid, noninvasive, and single-vesicle profiling of multiple AD-related protein biomarkers on EVs. The EV-CATCH enables controlled capture and on-demand release of serum EVs, ensuring high specificity and structural integrity of the isolated vesicles. Four core AD biomarkers on serum EVs were profiled at the individual vesicle level for stratification, and their clinical utility was assessed in two cohorts. The first cohort included 29 Aβ-PET-negative and 42 Aβ-PET-positive participants. In this group, the biomarker panel demonstrated an AUC of 0.873 in differentiating Aβ-PET status, further supporting its value in reflecting cerebral amyloid pathology. The second cohort consisted of 110 serum samples, comprising those from healthy controls as well as from subjects with mild cognitive impairment (MCI) and AD. Combined analysis of the four EV-associated biomarkers yielded high diagnostic accuracy, with areas under the receiver operating characteristic curves (AUCs) of 0.932 for MCI and 0.923 for AD. This clinically accessible single-vesicle method enables multiplexed and sensitive EV profiling for early AD diagnosis, accurate disease stratification and longitudinal monitoring, facilitating timely intervention thus promoting better patient prognosis.